Klinická farmakologie a farmacie – 3/2021

www.klinickafarmakologie.cz / Klin Farmakol Farm 2021; 35(3): 70–77 / KLINICKÁ FARMAKOLOGIE A FARMACIE 77 HLAVNÍ TÉMA Léčba mnohočetného myelomu v roce 2021 „ Nemocní s relapsemMMbyměli být léčeni s využitím jiných léků než v první linii, vol‑ ba závisí především na agresivitě relapsu, předešlé léčbě a jejím efektu, a celkovém stavu pacienta. „ Klíčovou molekulou pro léčbu relabova‑ ného MM je v současnosti lenalidomid a jeho kombinované režimy, zejména DRD, KRD, IRD či EloRD. „ V případě refrakterity na lenalidomid či při léčbě vyšší linie je obecným pravi‑ dlem volba léku/lékové skupiny, která dosud nebyla použita. Cílem je podání pokud možno trojkombinace s alespoň dvěma novými léky. „ Specifické skupiny nemocných – křehcí pacienti, nemocní s rizikovou cytogene‑ tikou, renálním selháním apod. by měli být léčeni individuálně podle zvláštních pravidel. „ Velkou nadějí budoucí léčby je imunote‑ rapie, spočívající v cílené aktivaci vlast‑ ního imunitního systému a jeho zacílení na nádorové buňky. Za podpory NV18–03-00500, IGA­ ‑LF-2021-001. LITERATURA 1. Rajkumar SV, Dimopoulos MA, Palumbo A et al. Internatio‑ nal Myeloma Working Group updated criteria for the diagno‑ sis of multiple myeloma. Lancet Oncol, 2014; 15: e538–e548. 2. Kostopoulos IV, Ntanasis‑Stathopoulos I, Gavriatopoulou M et al. Front Oncol, 2020; 10: 860. 3. Rajkumar SV. Multiple myeloma: 2020 update on diagno‑ sis, risk‑stratification and management. Am J Hematol, 2020; 95: 548–567. 4. Dimopoulos MA, Moreau P, Terpos E et al. Multiplemyeloma: EHA‑ESMOClinical Practice Guidelines for diagnosis, treatment and follow‑up. Ann Oncol, 2021; 32: 309–322. 5. Rajkumar SV. Sequencing of myeloma therapy: Finding the right path among many standards. Heamatol Oncol, 2021; 39: 68–72. 6. Moreau P, San Miguel J, Sonneveld P et al. Multiple myelo‑ ma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‑up. Ann Oncol. 2017;28: iv52–iv61. 7. Sonneveld P, Goldschmidt H, Rosinol L et al. Bortezomib­ ‑based versus nonbortezomib‑based induction treatment be‑ fore autologous stemcell transplantation in patients with pre‑ viously untreatedmultiple myeloma: a meta‑analysis of phase III randomized, controlled trials. J ClinOncol. 2013; 31: 3279–3287. 8. Moreau P, Hulin C, Macro M et al. VTD is superior to VCD pri‑ or to intensive therapy inmultiplemyeloma: results of the pro‑ spective IFM2013-04 trial. Blood. 2016; 127: 2569–2574. 9. Moreau P, Attal M, Hulin C et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and af‑ ter autologous stem‑cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open‑label, phase 3 study. Lancet. 2019; 394: 29–38. 10. Rosinol L, Hebraud B, Oriol A et al. Integrated analysis of bortezomiblenalidomide‑dexamethasone vs bortezomib­ ‑thalidomide‑dexamethasone in transplant‑eligible newly diagnosed myeloma. Clin Lymphoma Myeloma Leuk. 2019; 19(suppl): E1–E2. 11. Voorhees PM, Kaufman JL, Laubach JP et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant­ ‑eligible newly diagnosedmultiplemyeloma: the GRIFFIN trial. Blood. 2020; 136: 936–945. 12. Blanes M, Lahuerta JJ, Gonzalez JD et al. Intravenous busul‑ fan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan­ ‑only approach. Biol BloodMarrow Transplant. 2013; 19: 69–74. 13. Blanes M, Lorenzo JI, Ribas P et al. Intravenous busulfan plus melphalan versus melphalan alone as conditioning regi‑ men for patients with multiple myeloma. Ann Hematol. 2019; 98: 2013–2015. 14. Minarik J, Faber E, Raida L et al. 20 Years of Transplant Pro‑ gram inMultipleMyeloma – a Single Centre Experience. Blood, 2018; 132 (Suppl 1): 5749. 15. Kodad SG, Sutherland H, Limvorapitak W et al. Outpatient Autologous Stem Cell Transplants for Multiple Myeloma: Ana‑ lysis of Safety andOutcomes in a Tertiary Care Center. Clin LYm‑ phoma MYeloma Leuk, 2019; 19: 784–790. 16. Shah N, Cornelison AM, Saliba R et al. Inpatient vs outpatient autologous hematopoietic stemcell transplantation for multi‑ ple myeloma. Eur J Haematol, 2017; 99: 532–535. 17. Larsen K, Mohan M, Bailey C et al. Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission. Blood, 2020; 136 (Suppl 1): 44. 18. Cavo M, Gay F, Beksac M et al. Autologous haematopoie‑ tic stem‑cell transplantation versus bortezomib‑melphalan­ ‑prednisone, with or without bortezomib‑lenalidomide­ ‑dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosedmultiplemyeloma (EMN02/ HO95): a multicentre, randomised, open‑label, phase 3 study. Lancet Haematol. 2020; 7: e456–e468. 19. CavoM, Gay F, Patriarca F et al. Double autologous stemcell transplantation significantly prolongs progression‑free survival and overal survival in comparisonwith single autotransplantati‑ on in newly diagnosedmultiplemyeloma: an analysis of phase 3 EMN02/HO95 study. Blood. 2017; 130 (suppl 1): 401. 20. Stadtmauer EA, Pasquini MC, Blackwell B et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol. 2019; 37: 589–597. 21. Hari P, Pasquini M, Stadtmauer E et al. Long‑term follow‑up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiplemyeloma (MM). J Clin Oncol. 2020; 38(suppl 15): 8506. 22. Giralt S, Costa LJ, Maloney D et al. Tandem autologous­ ‑autologous versus autologous‑allogeneic hematopoietic stem cell transplant for patients with multiple myeloma: long‑term follow‑up results from the Blood and Marrow Transplant Cli‑ nical Trials Network 0102 Trial. Biol Blood Marrow Transplant. 2020; 26: 798–804. 23. Attal M, Lauwers‑Cances V, Marit G et al. Lenalidomidemain‑ tenance after stem‑cell transplantation for multiple myeloma. N Engl J Med. 2012; 366: 1782–1791. 24. McCarthy PL, Owzar K, Hofmeister CC et al. Lenalidomide after stem cell transplantation for multiple myeloma. N Engl J Med. 2012; 366: 1770–1781. 25. McCarthy PL, Holstein SA, Petrucci MT et al. Lenalidomide maintenance after autologous stem‑cell transplantation in newly diagnosed multiple myeloma: a meta‑analysis. J Clin Oncol. 2017; 35: 3279–3289. 26. Goldschmidt H, Lokhorst HM, Mai EK et al. Bortezomib be‑ fore and after high‑dose therapy in myeloma: long‑term re‑ sults from the phase III HOVON-65/GMMG‑HD4 trial. Leuke‑ mia. 2018; 32: 383–390. 27. Dimopoulos MA, Gay F, Schjesvold F et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE‑MM3): a double‑blind, randomised, placebo­ ‑controlled phase 3 trial. Lancet. 2019; 393: 253–264. 28. Durie BGM, Hoering A, Abidi MH et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem‑cell transplant (SWOG S0777): a randomised, openlabel, phase 3 trial. Lancet. 2017; 389: 519–527. 29. Mateos MV, Dimopoulos MA, Cavo M et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018; 378: 518–528. 30. Facon T, Kumar S, Plesner T et al. Daratumumab plus lena‑ lidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019; 380: 2104–2115. 31. Facon T, Kumar SK, Plesner T et al. Overall survival results with daratumumab, lenalidomide, and dexamethasone ver‑ sus lenalidomide and dexamethasone in transplant‑ineligible newly diagnosedmultiplemyeloma: phase 3MAIA study. Pre‑ sented at: European Hematology Association Annual Meeting; June 9–17, 2021; Virtual. Abstract LB1901 32. Dimopoulos MA, Oriol A, Hahi H et al. Daratumumab, Lena‑ lidomide, and Dexamethasone for MultipleMyeloma. N Engl J Med, 2016; 375: 1319–1331. 33. Stewart AK, Rajkumar SV, Dimopoulos MA et al. Carfilzomib, Lenalidomide, andDexamethasone for RelapsedMultipleMye‑ loma. N Engl J Med, 2015; 372: 142–152. 34. Moreau P, Masszi T, Grzasko N et al. Oral Ixazomib, Lenali‑ domide, and Dexamethasone for Multiple Myeloma. N Engl J Med, 2016; 374: 1621–1634. 35. Dimopoulos MA, Lonial S, White D et al. Elotuzumab, lena‑ lidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blo‑ od Cancer J, 2020; 10: 91. 36. Bahlis NJ, Dimopoulos MA, White DJ et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiplemyeloma: extended follow‑up of POLLUX, a randomi‑ zed, open‑label, phase 3 study. Leukemia, 2020; 34: 1875–1884. 37. Dimopoulos MA, Quach H, MAteos MV et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory mul‑ tiple myeloma (CANDOR): results from a randomised, multi‑ centre, open‑label, phase 3 study. Lancet, 2020; 396: 186–197. 38. Moreau P, Dimopoulos MA, Mikhael J et al. Isatuximab, car‑ filzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open‑label, randomised phase 3 trial. Lancet, 2021; https://doi.org/10.1016/S0140-6736(21)00592-4 39. Moreau P, Kumar SK, San Miguel J et al. Treatment of re‑ lapsed and refraktory multiple myelom: recommendations from the International Myeloma Working Group. Lancet On‑ col, 2021; 22: e105–118. 40. Kumar SK, Harrison SJ, Cavo M et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in pa‑ tients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double‑blind, multicentre, phase 3 trial. Lancet Oncol, 2020; 21: 1630–1642. 41. https://clinicaltrials.gov/ct2/show/NCT03732703 42. Teoh PJ, Chng WJ. CAR T‑cell therapy in multiple myelo‑ ma: more room for improvement. Blood Cancer J, 2021; 11: 84. 43. Munshi NC, Anderson LD, Shah N et al. Idecabtagene Vic‑ leucel in relapsed and refractory multiple myeloma. New Engl J Med, 2021; 384: 705–716 44. Madduri D, Usmani S, Jagannath S et al. Results from CAR‑ TITUDE-1: A Phase 1 b/2 study of JNJ-4528, a CAR‑T cell thera‑ py directed against B‑Cell Maturation Antigen (BCMA), in pati‑ ents with Relapsed and/or Refractory Multiple Myeloma (R/R MM). Blood, 2019; 134 (Suppl 1): 577.